Public Sector Pension Investment Board Increases Stock Position in Medtronic PLC $MDT

Public Sector Pension Investment Board increased its stake in shares of Medtronic PLC (NYSE:MDT) by 13.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 112,261 shares of the medical technology company’s stock after purchasing an additional 13,705 shares during the period. Public Sector Pension Investment Board’s holdings in Medtronic were worth $10,692,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in shares of Medtronic in the 2nd quarter worth $1,432,698,000. Guinness Asset Management LTD purchased a new position in Medtronic in the third quarter worth about $275,556,000. Vanguard Group Inc. grew its stake in shares of Medtronic by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after purchasing an additional 1,895,165 shares during the period. Bessemer Group Inc. increased its position in shares of Medtronic by 86.2% during the 3rd quarter. Bessemer Group Inc. now owns 2,538,029 shares of the medical technology company’s stock valued at $241,723,000 after purchasing an additional 1,174,765 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Medtronic by 332.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock worth $130,300,000 after purchasing an additional 1,148,803 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on MDT shares. Leerink Partners set a $120.00 target price on shares of Medtronic and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. UBS Group restated a “neutral” rating and issued a $104.00 price objective on shares of Medtronic in a research note on Wednesday, February 4th. Citigroup initiated coverage on Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 target price on the stock. Finally, Robert W. Baird set a $103.00 price target on Medtronic in a research report on Tuesday, December 16th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $111.21.

Medtronic Trading Down 1.3%

Medtronic stock opened at $99.57 on Monday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The firm’s 50 day moving average price is $99.28 and its 200-day moving average price is $96.46. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock has a market cap of $127.65 billion, a P/E ratio of 26.84, a PEG ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the business posted $1.26 EPS. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is currently 76.55%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA cleared Medtronic’s Stealth AXiS system — an integrated planning, navigation and robotics platform for spine surgery that expands the company’s procedural addressable market and supports hardware/software recurring revenue potential. This is a material product‑launch catalyst for spine and future cranial/ENT applications. PR Newswire
• Positive Sentiment: Independent coverage and price‑target lifts: Barclays initiated coverage with an Overweight and $116 PT, and Needham upgraded to Buy with a $121 PT — both signal analyst conviction that recent product momentum and margins support upside from current levels. Benzinga Needham Upgrade
• Positive Sentiment: Market commentary highlights improving returns/operational momentum that could support multiple expansion if sustained — a constructive narrative for longer‑term investors. Yahoo Finance
• Neutral Sentiment: Q3 FY2026 earnings preview: analysts outline what to watch in the upcoming report (revenue cadence, procedure volumes, and guidance) — an event that could be a short‑term catalyst but not new information. MSN Earnings Preview
• Neutral Sentiment: Dividend/income writeups underscore MDT’s ~2.8% yield and ways to generate cash flow; supportive for income investors but a limited driver of near‑term price moves. Benzinga Dividend
• Negative Sentiment: Geopolitical and China exposure risks: analysis highlights tariffs and China’s volume‑based procurement (VBP) program as potential headwinds to margins and growth in a key market — a meaningful downside risk that can compress near‑term revenue and investor sentiment. Seeking Alpha

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).